(Q46017035)

English

Valganciclovir as CMV reactivation prophylaxis in patients receiving alemtuzumab for marrow failure syndromes.

scientific article published on 9 May 2009

Statements

Valganciclovir as CMV reactivation prophylaxis in patients receiving alemtuzumab for marrow failure syndromes. (English)

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit